Abbott today announced the launch of its neuromodulation business’ next-generation delivery system, which will be used to streamline the implantation process for electrodes used as part of its Proclaim DRG neurostimulation system. The new system is intended to streamline the procedure when doctors implant the system in patients who are suffering from complex regional pain syndrome (CRPS) Type 1 and causalgia (CRPS Type 2) of the lower extremities, rare conditions that are considered more painful than childbirth or limb amputation.
The dorsal root ganglion – or DRG – is a cluster of nerve cells found along the spine that control pain signals from specific areas of the body, including the pelvis, groin, hip, knee, ankle and foot. Abbott developed Proclaim DRG therapy specifically to target this cluster of nerves, becoming the first and only DRG technology approved to treat CRPS of the lower limbs.
The DRG neurostimulation system consists of a small battery, often referred to as an implantable pulse generator (IPG), that produces the electrical stimulation, and thin wires, known as leads, that delivers the stimulation to a targeted area, in this case the DRG. Once implanted, targeted stimulation in this area can help address symptoms by disrupting pain signals before they can reach the spinal cord or brain.
The delivery system is an important part of the Proclaim DRG system because it enables physicians to carefully navigate and access the precise anatomy of the DRG when placing the system's electrodes. Designed for ease of use, the next-generation delivery system offers enhanced durability and maneuverability, which can streamline the implant procedure.
Placing a DRG lead involves accessing the epidural space with a needle and maneuvering the lead toward the DRG under image guidance. This delivery system is intended to allow physicians to implant the DRG system more efficiently.
